semaglutide new berlin Novo Nordisk announced headline results from STEP UP, a phase IIIb trial investigating subcutaneous 7.2 mg for obesity Month program now available from Weight Care Novo Nordisk expands lawsuits against

The Cleveland Clinic study includes nearly 8,000 patients who discontinued semaglutide and tirzepatide, common GLP-1 medications

Finally, ask what long-term looks like

Common user-reported outcomes include: Faster recovery timelines from tendon and ligament injuries (e.g., sprains, tears, tendinitis) Reduced joint pain and inflammation , especially in chronic overuse cases Improved mobility and function , even after prolonged downtime Noticeable benefits when combined with physical therapy or structured rehab protocols Many report using BPC-157 alongside TB500 for a synergistic approach to healing dense connective tissues , especially when muscle, tendon, and fascia are involved

doi: 10.1161/STROKEAHA.112.652545

(November 14, 2025)